Although large biotech stocks this year, the "ten times the shares" (ie, the stock rose more than 1000%) compared to last year's sharp decline, the relative decline in the rate of return, but they are impressive in this year's trend. Nevertheless, we still on the market capitalization of over USD 10 billion "big biotech stocks," did some research and found that biotech stocks in 2010, emerged a large number of winners, we also found some of them rose in 2011 the greatest potential for the stock.
Biohealth Investor has two assessment team, they were evaluated in 2011 the biggest upside potential of biotechnology stocks which, in 2010 and which the best performance so far.
So far in 2010 the big winner of biotechnology stocks have Illumina Inc. (ILMN), InterMune Inc. (ITMN), Incyte Corporation (INCY), Theravance Inc. (THRX) and ViroPharma Inc. (VPHM). The reason why this year we look at their reasons for skyrocketing, for their future beyond next year and next year were analyzed.
Our analysis shows that the market value of one billion and a higher level of biotech stocks, Dendreon Corporation (DNDN) up the greatest potential, the other with upside potential are Amgen Inc. (AMGN), Gilead Sciences, Inc. (GILD), Celgene Corporation (CELG), Human Genome Sciences, Inc. (HGSI), Incyte Corporation (INCY) and Acorda Therapeutics, Inc. (ACOR).